A lysophosphatidic acid (LPA) is a phospholipid derivative that can act as a signaling molecule. LPA acts as a potent mitogen due to its activation of three high affinity G-protein-coupled receptors called LPAR1, LPAR2, and LPAR3. Dysregulated LPA-signaling has been linked to cancer, and can lead to hyperproliferation, which may contribute to oncogenesis and metastasis. PA might also be associated with pruritus in individuals with cholestatic diseases. Lysophosphatidic acid receptor antagonists act by inhibiting the LPA receptor, thereby preventing it from binding to the signaling molecule lysophosphatidic acid. Lysophosphatidic acid receptor antagonists are in clinical trials for idiopathic pulmonary fibrosis, psoriasis, pulmonary fibrosis, and others. BMS, Horizon Therapeutics, and Apollo Endosurgery are some of the major players in the lysophosphatidic acid receptor antagonists market.
Drugs under the Pipeline for Lysophosphatidic Acid Receptor Antagonists:
- BMS-986278
- BMS-986020
- fipaxalparant (HZN-825)
- BMS-986337
- Lpathomab
- HL-001
Key Market Developments:
- In Mar 2022, Ube Industries and HiLung entered into a collaboration agreement to co-develop and conduct clinical trials for HL-001 in idiopathic pulmonary fibrosis.
- In June 2023, the FDA awarded Orphan Drug Designation to HL-001, an LPA-1 antagonist being developed for idiopathic pulmonary fibrosis by Ube Industries.
Clinical Activity and Developments of Lysophosphatidic Acid Receptor Antagonists:
Currently, there are more than 20 drug products in the lysophosphatidic acid receptor antagonists, including 12 approved drug products and the rest of them are in the clinical development phases.
- In Nov 2022, Horizon Therapeutics initiated enrolment in a phase-I/II open-label extension trial for diffuse scleroderma in the USA for Fipaxalparant.
- In July 2023, Bristol-Myers Squibb presented updated safety and efficacy data from the phase-II trial in idiopathic pulmonary fibrosis for BMS 986278, a LPA antagonist.
|
Molecule Name |
Number of Studies |
|
BMS-986278 |
9 |
|
BMS-986020 |
7 |
|
fipaxalparant (HZN-825) |
5 |
|
BMS-986337 |
1 |
|
Lpathomab |
1 |
Target Indication Analysis of Lysophosphatidic Acid Receptor Antagonists
Lysophosphatidic acid receptor antagonists are in clinical investigational phase for conditions such as idiopathic pulmonary fibrosis, psoriasis, diffuse scleroderma, systemic scleroderma, pulmonary fibrosis, and others.
Regional Analysis of Lysophosphatidic Acid Receptor Antagonists
Lysophosphatidic Acid Receptor Antagonists Market
According to the National Institutes of Health, worldwide, idiopathic pulmonary fibrosis (IPF)affects 13 to 20 out of every 1,00,000 people and about 1,00,00 people in the USA have IPF, and Asia-Pacific countries had the highest incidence and prevalence rate, followed by Europe, and North America. According to the Global Burden of Disease 2019, there were about 46,22,594 incident cases of psoriasis in 2019, with the highest incidence rate in high-income countries. According to the National Organization for Rare Diseases systemic scleroderma affects between 38 and 341 individuals per million throughout the world, and is more common in southern Europe, North America, and Australia. The increase in the number of disease cases will lead to the growth of the lysophosphatidic acid receptor antagonist’s market.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
BMS-986278, BMS-986020, fipaxalparant (HZN-825), BMS-986337, Lpathomab, and HL-001 are some of the drugs under the pipeline for lysophosphatidic acid receptor antagonists.
BMS, Horizon Therapeutics, and Apollo Endosurgery are some of the major players in the lysophosphatidic acid receptor antagonist’s market. Ans: BMS, Horizon Therapeutics, and Apollo Endosurgery are some of the major players in the lysophosphatidic acid receptor antagonist’s market.
Major indications for lysophosphatidic acid receptor antagonists are idiopathic pulmonary fibrosis, psoriasis, diffuse scleroderma, systemic scleroderma, and pulmonary fibrosis.
There are a total of six molecules in the clinical development phases for lysophosphatidic acid receptor antagonists.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- BMS
- Horizon Therapeutics
- Apollo Endosurgery